137
Views
5
CrossRef citations to date
0
Altmetric
Review

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach

, &
Pages 1591-1596 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yu Dong, Tao Xu, Dongfan Li, Hua Guo, Xusheng Du, Guangshun Li, Jiakuan Chen, Bo Wang, Peng Wang, Gang Yu, Xuan Zhao & Ruiqi Xue. (2022) NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer. Bioengineered 13:6, pages 14413-14425.
Read now

Articles from other publishers (4)

Edward S. Kim, Sigrid Balser, Klaus B. Rohr, Ragna Lohmann, Bernd Liedert & Dorothee Schliephake. (2022) Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC. JTO Clinical and Research Reports 3:1, pages 100248.
Crossref
Paul Zarogoulidis, Savvas Petanidis, Efrosini Kioseoglou, Kalliopi Domvri, Doxakis Anestakis & Konstantinos Zarogoulidis. (2015) MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cellular Signalling 27:8, pages 1576-1588.
Crossref
Mouldy Sioud, Phuong Westby, Julie Kristine E. Olsen & Anne Mobergslien. (2015) Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Molecular Therapy - Methods & Clinical Development 2, pages 15043.
Crossref
Claudia Omarini, Eirini Thanopoulou & Stephen R. D. Johnston. (2014) Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Research and Treatment 146:2, pages 245-258.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.